Polycythemia Vera, Myelofibrosis, Acute Graft | 合法藥品大搜索
ThemostcommonsideeffectsofJakafiinclude:forcertaintypesofMFandPV–lowplateletorredbloodcellcounts,bruising,dizziness,headache,anddiarrhea; ...
Important Safety InformationJakafi can cause serious side effects, including:
Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.
Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting...
Video – Clinical Trial Results with Steroid Refractory aGVHD ... | 合法藥品大搜索
Acute GVHD Treatment After Treatment With Steroids – What ... | 合法藥品大搜索
Jakafi® (ruxolitinib) Results From Acute GVHD Clinical Trials ... | 合法藥品大搜索
Acute Graft | 合法藥品大搜索
Video – What are the Signs & Symptoms of aGVHD | 合法藥品大搜索
Polycythemia Vera, Myelofibrosis, Acute Graft | 合法藥品大搜索
Support & Resources | Acute Graft | 合法藥品大搜索
Ruxolitinib Benefits Some Patients with Graft | 合法藥品大搜索
Ruxolitinib (Oral Route) Side Effects | 合法藥品大搜索
Side Effects of GVHD Treatment | 合法藥品大搜索
【捷可衛錠 10毫克】1.適用於治療中度風險或高風險之骨髓纖維化,包括原發性骨髓纖維化、真性紅血球增多症後骨髓纖維化、或血小板增多症後骨髓纖維化。2.適用於接受hydroxyurea 治療後有抗藥性或無耐受性的真性紅血球增多症。
藥品名稱:捷可衛錠10毫克許可證字號:衛部藥輸字第026707號許可證種類:製 劑適應症:1.適用於治療中度風險或高風險之骨髓纖維...
【捷可衛錠 20毫克】1.適用於治療中度風險或高風險之骨髓纖維化,包括原發性骨髓纖維化、真性紅血球增多症後骨髓纖維化、或血小板增多症後骨髓纖維化。2.適用於接受hydroxyurea 治療後有抗藥性或無耐受性的真性紅血球增多症。
藥品名稱:捷可衛錠20毫克許可證字號:衛部藥輸字第026361號許可證種類:製 劑適應症:1.適用於治療中度風險或高風險之骨髓纖維...
【捷可衛錠 5毫克】1.適用於治療中度風險或高風險之骨髓纖維化,包括原發性骨髓纖維化、真性紅血球增多症後骨髓纖維化、或血小板增多症後骨髓纖維化。2.適用於接受hydroxyurea 治療後有抗藥性或無耐受性的真性紅血球增多症。
藥品名稱:捷可衛錠5毫克許可證字號:衛部藥輸字第026359號許可證種類:製 劑適應症:1.適用於治療中度風險或高風險之骨髓纖維...
【捷可衛錠 15毫克】1.適用於治療中度風險或高風險之骨髓纖維化,包括原發性骨髓纖維化、真性紅血球增多症後骨髓纖維化、或血小板增多症後骨髓纖維化。2.適用於接受hydroxyurea 治療後有抗藥性或無耐受性的真性紅血球增多症。
藥品名稱:捷可衛錠15毫克許可證字號:衛部藥輸字第026360號許可證種類:製 劑適應症:1.適用於治療中度風險或高風險之骨髓纖維...